Matinas BioPharma Provides Comment on Impact of Vascepa® Patent Litigation on MAT9001 and Update on COVID-19 Pandemic’s Effect on Business Operations and Clinical Programs
Matinas Biopharma Holdings, Inc. (MTNB)
NASDAQ:AMEX Investor Relations:
ir.matinasbiopharma.com
Company Research
Source: GlobeNewswire
BEDMINSTER, N.J., March 31, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today commented on the recent United States District Court decision to invalidate patents related to Amarin Corporation’s Vascepa and also provided an update on the effect of the rapidly evolving COVID-19 pandemic on its business operations and clinical development programs. Impact of Invalidity Decision on Amarin Corporation’s Vascepa® Patents Matinas is aware of the United States District Court for the District of Nevada’s ruling yesterday in favor of the generic companies in Amarin Corporation’s patent litigation against two filers of abbreviated new drug applications, or ANDAs, for Amarin’s Vascepa. Amarin issued a statement yesterday indicating that it will appeal and vigorously defend its intellectual property, while seeking an injunction to prevent a potential launch of generic versions of Vascepa. In noting that an ANDA for
Show less
Read more
Impact Snapshot
Event Time:
MTNB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MTNB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MTNB alerts
High impacting Matinas Biopharma Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
MTNB
News
- Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024GlobeNewswire
- In Vivo Efficacy of Matinas BioPharma's Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy [Yahoo! Finance]Yahoo! Finance
- Lundquist Investigator Dr. Ashraf Ibrahim Is the Lead Author in the Landmark Study on Pioneering Oral Fungal Infection Treatment Showing Promise in Preclinical Trials [Yahoo! Finance]Yahoo! Finance
- In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and ChemotherapyGlobeNewswire
- Matinas BioPharma Prices $10 Million Registered Direct Offering [Yahoo! Finance]Yahoo! Finance
MTNB
Earnings
- 5/10/23 - In-Line
MTNB
Sec Filings
- 4/5/24 - Form 8-K
- 4/4/24 - Form 424B5
- 3/28/24 - Form 8-K
- MTNB's page on the SEC website